Document:

Exhibit 10.3

 

REGISTRATION RIGHTS AGREEMENT

 

This REGISTRATION RIGHTS
AGREEMENT (this “Agreement”), dated as of _____, 2022, is by and among VSee Health, Inc. (f/k/a Digital Health
Acquisition Corp.), a Delaware corporation with offices located at 980 N. Federal Hwy #304, Boca Raton, FL 33432 (the “Company”),
and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).

 

RECITALS

 

A.             In
connection with the Amended and Restated Securities Purchase Agreement by and among the parties hereto, dated as of October 6,
2022 (the “Securities Purchase Agreement”), the Company has agreed, upon the terms and subject to the conditions
of the Securities Purchase Agreement, to issue and sell to each Buyer (i) the Preferred Shares (as defined in the Securities
Purchase Agreement) which will be convertible into Conversion Shares (as defined in the Securities Purchase Agreement) in accordance
with the terms of the Certificate of Designations (as defined in the Securities Purchase Agreement) and (ii) the Warrants (as
defined in the Securities Purchase Agreement) which will be exercisable to purchase Warrant Shares (as defined in the Securities
Purchase Agreement) in accordance with the terms of the Warrants.

 

B.             To
induce the Buyers to consummate the transactions contemplated by the Securities Purchase Agreement, the Company has agreed to provide
certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar
successor statute (collectively, the “1933 Act”), and applicable state securities laws.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and each of the Buyers hereby agree as follows:

 

1.              Definitions.

 

Capitalized terms used herein
and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement. As used in this Agreement,
the following terms shall have the following meanings:

 

(a)            “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” 
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.

 

     

     

    

 

(b)            “Closing
Date” shall have the meaning set forth in the Securities Purchase Agreement.

 

(c)            “Effective
Date” means the date that the applicable Registration Statement has been declared effective by the SEC.

 

(d)            “Effectiveness
Deadline” means (i) with respect to the initial Registration Statement required to be filed pursuant to Section 2(a),
the earlier of the (A) 90th calendar day (or, if subject to a full review by the SEC, the 120th calendar day)
after the Closing Date and (B) 2nd Business Day after the date the Company is notified (orally or in writing, whichever is earlier)
by the SEC that such Registration Statement will not be reviewed or will not be subject to further review and (ii) with respect
to any additional Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the earlier of
the (A) 90th calendar day (or, if subject to a full review by the SEC, the 120th calendar day) following the
date on which the Company was required to file such additional Registration Statement and (B) 2nd Business Day after
the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be
reviewed or will not be subject to further review.

 

(e)            “Filing
Deadline” means (i) with respect to the initial Registration Statement required to be filed pursuant to Section 2(a),
the 30th calendar day after the Closing Date and (ii) with respect to any additional Registration Statements that may
be required to be filed by the Company pursuant to this Agreement, the date on which the Company was required to file such additional
Registration Statement pursuant to the terms of this Agreement.

 

(f)            “Investor”
means a Buyer or any transferee or assignee of any Registrable Securities, Preferred Shares or Warrants, as applicable, to whom a Buyer
assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section 9
and any transferee or assignee thereof to whom a transferee or assignee of any Registrable Securities, Preferred Shares or Warrants,
as applicable, assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance
with Section 9.

 

(g)            “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
or a government or any department or agency thereof.

 

(h)            “register,”
 “registered,” and “registration” refer to a registration effected by preparing and filing one or
more Registration Statements in compliance with the 1933 Act and pursuant to Rule 415 and the declaration of effectiveness of such
Registration Statement(s) by the SEC.

 

(i)             “Registrable
Securities” means (i) the Conversion Shares, (ii) the Warrant Shares and (iii) any capital stock of the Company
issued or issuable with respect to the Conversion Shares, the Warrant Shares, the Preferred Shares or the Warrants, including, without
limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares
of capital stock of the Company into which the shares of Common Stock (as defined in the Certificate of Designations) are converted or
exchanged and shares of capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common Stock are converted
or exchanged, in each case, without regard to any limitations on conversion of the Preferred Shares or exercise of the Warrants.

 

    2 

     

    

 

(j)            “Registration
Statement” means a registration statement or registration statements of the Company filed under the 1933 Act covering Registrable
Securities.

 

(k)            “Required
Holders” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(l)            “Required
Registration Amount” means, as of any time of determination, 200% of the sum of (i) the maximum number of Conversion Shares
issuable upon conversion of the Preferred Shares (assuming for purposes hereof that (x) the Preferred Shares are convertible at
the Floor Price (as defined in the Certificate of Designations) and (y) dividends on the Preferred Shares shall accrue through the
eighteen month anniversary of the Closing Date and will be converted in shares of Common Stock at the Floor Price and any such conversion
shall not take into account any limitations on the conversion of the Preferred Shares set forth in the Certificate of Designations) and
(ii) the maximum number of Warrant Shares issuable upon exercise of the Warrants (without taking into account any limitations on
the exercise of the Warrants set forth therein), all subject to adjustment as provided in Section 2(d) and/or Section 2(f).

 

(m)            “Rule 144”
means Rule 144 promulgated by the SEC under the 1933 Act, as such rule may be amended from time to time, or any other similar
or successor rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public
without registration.

 

(n)            “Rule 415”
means Rule 415 promulgated by the SEC under the 1933 Act, as such rule may be amended from time to time, or any other similar
or successor rule or regulation of the SEC providing for offering securities on a continuous or delayed basis.

 

(o)            “SEC”
means the United States Securities and Exchange Commission or any successor thereto.

 

2.              Registration.

 

(a)            Mandatory
Registration. The Company shall prepare and, as soon as practicable, but in no event later than the Filing Deadline, file with the
SEC an initial Registration Statement on Form S-1 covering the resale of all of the Registrable Securities, provided that such initial
Registration Statement shall register for resale at least the number of shares of Common Stock equal to the Required Registration Amount
as of the date such Registration Statement is initially filed with the SEC. Such initial Registration Statement, and each other Registration
Statement required to be filed pursuant to the terms of this Agreement, shall contain (except if otherwise directed by the Required Holders)
the “Selling Stockholders” and “Plan of Distribution” sections in substantially the form attached
hereto as Exhibit B. The Company shall use its best efforts to have such initial Registration Statement, and each other Registration
Statement required to be filed pursuant to the terms of this Agreement, declared effective by the SEC as soon as practicable, but in
no event later than the applicable Effectiveness Deadline for such Registration Statement.

 

    3 

     

    

 

(b)            Legal
Counsel. Subject to Section 5 hereof, Kelley Drye & Warren LLP, counsel solely to the lead investor (“Legal
Counsel”) shall review and oversee any registration, solely on behalf of the lead investor, pursuant to this Section 2.

 

(c)            Ineligibility
to Use Form S-3. The Company undertakes to register the resale of the Registrable Securities on Form S-3 as soon as
such form is available, provided that the Company shall maintain the effectiveness of all Registration Statements then in effect until
such time as a Registration Statement on Form S-3 covering the resale of all the Registrable Securities has been declared effective
by the SEC and the prospectus contained therein is available for use.

 

(d)            Sufficient
Number of Shares Registered. In the event the number of shares available under any Registration Statement is insufficient to cover
all of the Registrable Securities required to be covered by such Registration Statement or an Investor’s allocated portion of the
Registrable Securities pursuant to Section 2(h), the Company shall amend such Registration Statement (if permissible), or file with
the SEC a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover at least the Required
Registration Amount as of the Trading Day immediately preceding the date of the filing of such amendment or new Registration Statement,
in each case, as soon as practicable, but in any event not later than fifteen (15) Trading Days after the necessity therefor arises (but
taking account of any Staff position with respect to the date on which the Staff will permit such amendment to the Registration Statement
and/or such new Registration Statement (as the case may be) to be filed with the SEC); provided however that in the event that such amendment
cannot be so timely filed due to delays caused by the receipt of the Company’s independent auditors’ consent(s), such fifteen
(15) Trading Days shall be extended to (30) Trading Days. The Company shall use its best efforts to cause such amendment to such Registration
Statement and/or such new Registration Statement (as the case may be) to become effective as soon as practicable following the filing
thereof with the SEC, but in no event later than the applicable Effectiveness Deadline for such Registration Statement. For purposes
of the foregoing provision, the number of shares available under a Registration Statement shall be deemed “insufficient to cover
all of the Registrable Securities” if at any time the number of shares of Common Stock available for resale under the applicable
Registration Statement is less than the product determined by multiplying (i) the Required Registration Amount as of such time by
(ii) 0.90. The calculation set forth in the foregoing sentence shall be made without regard to any limitations on conversion, amortization
and/or redemption of the Preferred Shares or exercise of the Warrants (and such calculation shall assume (A) that the Preferred
Shares are then convertible in full into shares of Common Stock at the then prevailing Conversion Rate (as defined in the Certificate
of Designations), (B) the initial outstanding principal amount of the Preferred Shares remains outstanding through the scheduled
Maturity Date (as defined in the Certificate of Designations) and no redemptions of the Preferred Shares occur prior to the scheduled
Maturity Date and (C) the Warrants are then exercisable in full into shares of Common Stock at the then prevailing Exercise Price
(as defined in the Warrants)).

 

    4 

     

    

 

(e)            Effect
of Failure to File and Obtain and Maintain Effectiveness of any Registration Statement. If (i) a Registration Statement covering
the resale of all of the Registrable Securities required to be covered thereby (disregarding any reduction pursuant to Section 2(f))
and required to be filed by the Company pursuant to this Agreement is (A) not filed with the SEC on or before the Filing Deadline
for such Registration Statement (a “Filing Failure”) (it being understood that if the Company files a Registration
Statement without affording each Investor and Legal Counsel the opportunity to review and comment on the same as required by Section 3(c) hereof,
the Company shall be deemed to not have satisfied this clause (i)(A) and such event shall be deemed to be a Filing Failure)
or (B) not declared effective by the SEC on or before the Effectiveness Deadline for such Registration Statement (an “Effectiveness
Failure”) (it being understood that if on the Business Day immediately following the Effective Date for such Registration Statement
the Company shall not have filed a “final” prospectus for such Registration Statement with the SEC under Rule 424(b) in
accordance with Section 3(b) (whether or not such a prospectus is technically required by such rule), the Company shall be
deemed to not have satisfied this clause (i)(B) and such event shall be deemed to be an Effectiveness Failure), (ii) other
than during an Allowable Grace Period (as defined below), on any day after the Effective Date of a Registration Statement sales of all
of the Registrable Securities required to be included on such Registration Statement (disregarding any reduction pursuant to Section 2(f))
cannot be made pursuant to such Registration Statement (including, without limitation, because of a failure to keep such Registration
Statement effective, a failure to disclose such information as is necessary for sales to be made pursuant to such Registration Statement,
a suspension or delisting of (or a failure to timely list) the shares of Common Stock on the Principal Market (as defined in the Securities
Purchase Agreement) or any other limitations imposed by the Principal Market, or a failure to register a sufficient number of shares
of Common Stock or by reason of a stop order) or the prospectus contained therein is not available for use for any reason (a “Maintenance
Failure”), or (iii) if a Registration Statement is not effective for any reason or the prospectus contained therein is
not available for use for any reason, and either (x) the Company fails for any reason to satisfy the requirements of Rule 144(c)(1),
including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (y) the
Company has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the Company shall
fail to satisfy any condition set forth in Rule 144(i)(2) (a “Current Public Information Failure”) as a
result of which any of the Investors are unable to sell Registrable Securities without restriction under Rule 144 (including, without
limitation, volume restrictions), then, as partial relief for the damages to any holder by reason of any such delay in, or reduction
of, its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of any other remedies available at
law or in equity, including, without limitation, specific performance), the Company shall pay to each holder of Registrable Securities
relating to such Registration Statement an amount in cash equal to two percent (2%) of such Investor’s Purchase Price (as defined
in the Securities Purchase Agreement) (1) on the date of such Filing Failure, Effectiveness Failure, Maintenance Failure or Current
Public Information Failure, as applicable, and (2) on every thirty (30) day anniversary of (I) a Filing Failure until such
Filing Failure is cured; (II) an Effectiveness Failure until such Effectiveness Failure is cured; (III) a Maintenance Failure
until such Maintenance Failure is cured; and (IV) a Current Public Information Failure until the earlier of (i) the date such
Current Public Information Failure is cured and (ii) such time that such public information is no longer required pursuant to Rule 144
(in each case, pro rated for periods totaling less than thirty (30) days). The payments to which a holder of Registrable Securities shall
be entitled pursuant to this Section 2(e) are referred to herein as “Registration Delay Payments.” Following
the initial Registration Delay Payment for any particular event or failure (which shall be paid on the date of such event or failure,
as set forth above), without limiting the foregoing, if an event or failure giving rise to the Registration Delay Payments is cured prior
to any thirty (30) day anniversary of such event or failure, then such Registration Delay Payment shall be made on the third (3rd)
Business Day after such cure. In the event the Company fails to make Registration Delay Payments in a timely manner in accordance with
the foregoing, such Registration Delay Payments shall bear interest at the rate of two percent (2%) per month (prorated for partial months)
until paid in full. Notwithstanding the foregoing, no Registration
Delay Payments shall be owed to an Investor (other than with respect to a Maintenance Failure resulting from a suspension or delisting
of (or a failure to timely list) the shares of Common Stock on the Principal Market) with respect to any period during which all of such
Investor’s Registrable Securities may be sold by such Investor without restriction under Rule 144 (including, without limitation,
volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2),
if applicable).

 

    5 

     

    

  

(f)            Offering.
Notwithstanding anything to the contrary contained in this Agreement, but subject to the payment of the Registration Delay Payments pursuant
to Section 2(e), in the event the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering
pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities by, or on behalf
of, the Company, or in any other manner, such that the Staff or the SEC do not permit such Registration Statement to become
effective and used for resales in a manner that does not constitute such an offering and that permits the continuous resale at the market
by the Investors participating therein (or as otherwise may be acceptable to each Investor) without being named therein as
an “underwriter,” then the Company shall reduce the number of shares to be included in such Registration Statement by all
Investors until such time as the Staff and the SEC shall so permit such Registration Statement to become effective as aforesaid.
In making such reduction, the Company shall reduce the number of shares to be included by all Investors on a pro rata basis (based upon
the number of Registrable Securities otherwise required to be included for each Investor) unless the inclusion of shares by a particular
Investor or a particular set of Investors are resulting in the Staff or the SEC’s “by or on behalf of the Company”
offering position, in which event the shares held by such Investor or set of Investors shall be the only shares subject to reduction
(and if by a set of Investors on a pro rata basis by such Investors or on such other basis as would result in the exclusion of the least
number of shares by all such Investors); provided, that, with respect to such pro rata portion allocated to any Investor, such Investor
may elect the allocation of such pro rata portion among the Registrable Securities of such Investor. In addition, in the event that the
Staff or the SEC requires any Investor seeking to sell securities under a Registration Statement filed pursuant to this Agreement to
be specifically identified as an “underwriter” in order to permit such Registration Statement to become effective, and such
Investor does not consent to being so named as an underwriter in such Registration Statement, then, in each such case, the Company shall
reduce the total number of Registrable Securities to be registered on behalf of such Investor, until such time as the
Staff or the SEC does not require such identification or until such Investor accepts such identification and the manner thereof. Any
reduction pursuant to this paragraph will first reduce all Registrable Securities other than those issued pursuant to the Securities
Purchase Agreement. In the event of any reduction in Registrable Securities pursuant to this paragraph, an affected Investor
shall have the right to require, upon delivery of a written request to the Company signed by such Investor, the Company to file a registration
statement within twenty (20) days of such request (subject to any restrictions imposed by Rule 415 or required by the Staff
or the SEC) for resale by such Investor in a manner acceptable to such Investor, and the Company shall following such request cause
to be and keep effective such registration statement in the same manner as otherwise contemplated in this Agreement for registration
statements hereunder, in each case until such time as: (i) all Registrable Securities held by such Investor have been registered
and sold pursuant to an effective Registration Statement in a manner acceptable to such Investor or (ii) all Registrable Securities
may be resold by such Investor without restriction (including, without limitation, volume limitations) pursuant to Rule 144
(taking account of any Staff position with respect to “affiliate” status) and
without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or (iii) such
Investor agrees to be named as an underwriter in any such Registration Statement in a manner acceptable to such Investor as to all Registrable
Securities held by such Investor and that have not theretofore been included in a Registration Statement under this Agreement (it being
understood that the special demand right under this sentence may be exercised by an Investor multiple times and with respect to limited
amounts of Registrable Securities in order to permit the resale thereof by such Investor as contemplated above).

 

    6 

     

    

 

(g)            Piggyback
Registrations. Without limiting any obligation of the Company hereunder or under the Securities Purchase Agreement, if there is not
an effective Registration Statement covering all of the Registrable Securities or the prospectus contained therein is not available for
use and the Company shall determine to prepare and file with the SEC a registration statement or offering statement relating to an offering
for its own account or the account of others under the 1933 Act of any of its equity securities (other than on Form S-4 or Form S-8
(each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with
any acquisition of any entity or business or equity securities issuable in connection with the Company’s stock option or other
employee benefit plans), then the Company shall deliver to each Investor a written notice of such determination and, if within fifteen (15)
days after the date of the delivery of such notice, any such Investor shall so request in writing, the Company shall include in such
registration statement or offering statement all or any part of such Registrable Securities such Investor requests to be registered;
provided, however, the Company shall not be required to register any Registrable Securities pursuant to this Section 2(g) that
are eligible for resale pursuant to Rule 144 without restriction (including, without limitation, volume restrictions) and without
the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or that are the
subject of a then-effective Registration Statement.

 

    7 

     

    

 

(h)            Allocation
of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement and any increase in
the number of Registrable Securities included therein shall be allocated pro rata among the Investors based on the number of Registrable
Securities held by each Investor at the time such Registration Statement covering such initial number of Registrable Securities or increase
thereof is declared effective by the SEC. In the event that an Investor sells or otherwise transfers any of such Investor’s Registrable
Securities, each transferee or assignee (as the case may be) that becomes an Investor shall be allocated a pro rata portion of the then-remaining
number of Registrable Securities included in such Registration Statement for such transferor or assignee (as the case may be). Any shares
of Common Stock included in a Registration Statement and which remain allocated to any Person which ceases to hold any Registrable Securities
covered by such Registration Statement shall be allocated to the remaining Investors, pro rata based on the number of Registrable Securities
then held by such Investors which are covered by such Registration Statement.

 

(i)            No
Inclusion of Other Securities. The Company shall in no event include any securities other than Registrable Securities on any Registration
Statement filed in accordance herewith without the prior written consent of the Required Holders. Except as described on Schedule 2(i) attachd
hereto, until the Applicable Date (as defined in the Securities Purchase Agreement), the Company shall not enter into any agreement providing
any registration rights to any of its security holders, except as otherwise permitted under the Securities Purchase Agreement.

 

3.              Related
Obligations.

 

The Company shall use its
best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof,
and, pursuant thereto, the Company shall have the following obligations:

 

(a)            The
Company shall promptly prepare and file with the SEC a Registration Statement with respect to all the Registrable Securities (but in
no event later than the applicable Filing Deadline) and use its best efforts to cause such Registration Statement to become effective
as soon as practicable after such filing (but in no event later than the Effectiveness Deadline). Subject to Allowable Grace Periods,
the Company shall keep each Registration Statement effective (and the prospectus contained therein available for use) pursuant to Rule 415
for resales by the Investors on a delayed or continuous basis at then-prevailing market prices (and not fixed prices) at all times until
the earlier of (i) the date as of which all of the Investors may sell all of the Registrable Securities required to be covered by
such Registration Statement (disregarding any reduction pursuant to Section 2(f)) without restriction pursuant to Rule 144
(including, without limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or
Rule 144(i)(2), if applicable) or (ii) the date on which the Investors shall have sold all of the Registrable Securities covered
by such Registration Statement (the “Registration Period”). Notwithstanding anything to the contrary contained in
this Agreement, the Company shall ensure that, when filed and at all times while effective, each Registration Statement (including, without
limitation, all amendments and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements
thereto) used in connection with such Registration Statement (1) shall not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in
the light of the circumstances in which they were made) not misleading and (2) will disclose (whether directly or through incorporation
by reference to other SEC filings to the extent permitted) all material information regarding the Company and its securities. The Company
shall submit to the SEC, within two (2) Business Days after the later of the date that (i) the Company learns that no review
of a particular Registration Statement will be made by the Staff or that the Staff has no further comments on a particular Registration
Statement (as the case may be) and (ii) the consent of Legal Counsel is obtained pursuant to Section 3(c) (which consent
shall be immediately sought), a request for acceleration of effectiveness of such Registration Statement to a time and date not later
than twenty-four (24) hours after the submission of such request. The Company shall respond in writing to comments made by the SEC
in respect of a Registration Statement as soon as reasonably practicable, but in no event later than fifteen (15) Trading Days after
the receipt of comments by or notice from the SEC that an amendment is required in order for a Registration Statement to be declared
effective; provided however that in the event that such amendment cannot be so timely filed due to delays caused by (i) responses
to accounting comments made by the SEC or (ii) the receipt of the Company’s independent auditors’ consent(s), such fifteen
(15) Trading Days shall be extended to (30) Trading Days.

 

    8 

     

    

 

(b)            Subject
to Section 3(r) of this Agreement, the Company shall prepare and file with the SEC such amendments (including, without limitation,
post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with each such Registration
Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the 1933 Act, as may be necessary to keep each
such Registration Statement effective at all times during the Registration Period for such Registration Statement, and, during such period,
comply with the provisions of the 1933 Act with respect to the disposition of all Registrable Securities of the Company required to be
covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance
with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement; provided, however,
by 8:30 a.m. (New York time) on the Business Day immediately following each Effective Date, the Company shall file with the SEC
in accordance with Rule 424(b) under the 1933 Act the final prospectus to be used in connection with sales pursuant to the
applicable Registration Statement (whether or not such a prospectus is technically required by such rule). In
the case of amendments and supplements to any Registration Statement which are required to be filed pursuant to this Agreement (including,
without limitation, pursuant to this Section 3(b)) by reason of the Company filing a report on Form 8-K, Form 10-Q or
Form 10-K or any analogous report under the Securities Exchange Act of 1934, as amended (the “1934 Act”), the
Company shall, if permitted under the applicable rules and regulations of the SEC, have incorporated such report by reference into
such Registration Statement, if applicable, or shall file such amendments or supplements with the SEC on the same day on which the 1934
Act report is filed which created the requirement for the Company to amend or supplement such Registration Statement.

 

    9 

     

    

 

(c)            The
Company shall (A) permit Legal Counsel and legal counsel for each other Investor to review and comment upon (i) each Registration
Statement at least five (5) Business Days prior to its filing with the SEC and (ii) all amendments and supplements to each
Registration Statement (including, without limitation, the prospectus contained therein) (except for Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports) within a reasonable number
of days prior to their filing with the SEC, and (B) not file any Registration Statement or amendment or supplement thereto in a
form to which Legal Counsel or any legal counsel for any other Investor reasonably objects. The Company shall not submit a request for
acceleration of the effectiveness of a Registration Statement or any amendment or supplement thereto or to any prospectus contained therein
without the prior consent of Legal Counsel, which consent shall not be unreasonably withheld. The Company shall promptly furnish to Legal
Counsel and legal counsel for each other Investor, without charge, (i) copies of any correspondence from the SEC or the Staff to
the Company or its representatives relating to each Registration Statement, provided that such correspondence shall not contain any material,
non-public information regarding the Company or any of its Subsidiaries (as defined in the Securities Purchase Agreement), (ii) after
the same is prepared and filed with the SEC, one (1) copy of each Registration Statement and any amendment(s) and supplement(s) thereto,
including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by an
Investor, and all exhibits and (iii) upon the effectiveness of each Registration Statement, one (1) copy of the prospectus
included in such Registration Statement and all amendments and supplements thereto. The Company shall reasonably cooperate with Legal
Counsel and legal counsel for each other Investor in performing the Company’s obligations pursuant to this Section 3.

 

(d)            The
Company shall promptly furnish to each Investor whose Registrable Securities are included in any Registration Statement, without charge,
(i) after the same is prepared and filed with the SEC, at least one (1) copy of each Registration Statement and any amendment(s) and
supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by
reference, if requested by an Investor, all exhibits and each preliminary prospectus, (ii) upon the effectiveness of each Registration
Statement, ten (10) copies of the prospectus included in such Registration Statement and all amendments and supplements thereto
(or such other number of copies as such Investor may reasonably request from time to time) and (iii) such other documents, including,
without limitation, copies of any preliminary or final prospectus, as such Investor may reasonably request from time to time in order
to facilitate the disposition of the Registrable Securities owned by such Investor.

 

(e)            The
Company shall use its best efforts to (i) register and qualify, unless an exemption from registration and qualification applies,
the resale by Investors of the Registrable Securities covered by a Registration Statement under such other securities or “blue
sky” laws of all applicable jurisdictions in the United States, (ii) prepare and file in those jurisdictions, such amendments
(including, without limitation, post-effective amendments) and supplements to such registrations and qualifications as may be necessary
to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain
such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably
necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, the Company shall not
be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 3(e), (y) subject itself to general taxation in any such jurisdiction,
or (z) file a general consent to service of process in any such jurisdiction.
The Company shall promptly notify Legal Counsel, legal counsel for each other Investor and each Investor who holds Registrable Securities
of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable
Securities for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual
notice of the initiation or threatening of any proceeding for such purpose.

 

    10 

     

    

 

(f)            The
Company shall notify Legal Counsel, legal counsel for each other Investor and each Investor in writing of the happening of any event,
as promptly as practicable after becoming aware of such event, as a result of which the prospectus included in a Registration Statement,
as then in effect, may include an untrue statement of a material fact or omission to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided that
in no event shall such notice contain any material, non-public information regarding the Company or any of its Subsidiaries), and, subject
to Section 3(r), promptly prepare a supplement or amendment to such Registration Statement and such prospectus contained therein
to correct such untrue statement or omission and deliver ten (10) copies of such supplement or amendment to Legal Counsel, legal
counsel for each other Investor and each Investor (or such other number of copies as Legal Counsel, legal counsel for each other Investor
or such Investor may reasonably request). The Company shall also promptly notify Legal Counsel, legal counsel for each other Investor
and each Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, when
a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered
to Legal Counsel, legal counsel for each other Investor and each Investor by e-mail on the same day of such effectiveness and by overnight
mail), and when the Company receives written notice from the SEC that a Registration Statement or any post-effective amendment will be
reviewed by the SEC, (ii) of any request by the SEC for amendments or supplements to a Registration Statement or related prospectus
or related information, (iii) of the Company’s reasonable determination that a post-effective amendment to a Registration
Statement would be appropriate; and (iv) of the receipt of any request by the SEC or any other federal or state governmental authority
for any additional information relating to the Registration Statement or any amendment or supplement thereto or any related prospectus.
The Company shall respond as promptly as practicable to any comments received from the SEC with respect to each Registration Statement
or any amendment thereto (it being understood and agreed that the Company’s response to any such comments shall be delivered to
the SEC no later than fifteen (15) Trading Days after the receipt thereof; provided however that in the event that such amendment
cannot be so timely filed due to delays caused by (i) responses to accounting comments made by the SEC or (ii) the receipt
of the Company’s independent auditors’ consent(s), such fifteen (15) Trading Days shall be extended to (30) Trading Days).

 

    11 

     

    

 

(g)            The
Company shall (i) use its best efforts to prevent the issuance of any stop order or other suspension of effectiveness of each Registration
Statement or the use of any prospectus contained therein, or the suspension of the qualification, or the loss of an exemption from qualification,
of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal
of such order or suspension at the earliest possible moment and (ii) notify Legal Counsel, legal counsel for each other Investor
and each Investor who holds Registrable Securities of the issuance of such order and the resolution thereof or its receipt of actual
notice of the initiation or threat of any proceeding for such purpose.

 

(h)            If
any Investor may be required under applicable securities law to be described in any Registration Statement as an underwriter and such
Investor consents to so being named an underwriter, at the request of any Investor, the Company shall furnish to such Investor, on the
date of the effectiveness of such Registration Statement and thereafter from time to time on such dates as an Investor may reasonably
request (i) a letter, dated such date, from the Company’s independent certified public accountants in form and substance as
is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the
Investors, and (ii) an opinion, dated as of such date, of counsel representing the Company for purposes of such Registration Statement,
in form, scope and substance as is customarily given in an underwritten public offering, addressed to the Investors.

 

(i)            If
any Investor may be required under applicable securities law to be described in any Registration Statement as an underwriter and such
Investor consents to so being named an underwriter, upon the written request of such Investor, the Company shall make available for inspection
by (i) such Investor, (ii) legal counsel for such Investor and (iii) one (1) firm of accountants or other agents
retained by such Investor (collectively, the “Inspectors”), all pertinent financial and other records, and pertinent
corporate documents and properties of the Company (collectively, the “Records”), as shall be reasonably deemed necessary
by each Inspector, and cause the Company’s officers, directors and employees to supply all information which any Inspector may
reasonably request; provided, however, each Inspector shall agree in writing to hold in strict confidence and not to make any disclosure
(except to such Investor) or use of any Record or other information which the Company’s board of directors determines in good faith
to be confidential, and of which determination the Inspectors are so notified, unless (1) the disclosure of such Records is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (2) the
release of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of competent
jurisdiction, or (3) the information in such Records has been made generally available to the public other than by disclosure in
violation of this Agreement or any other Transaction Document (as defined in the Securities Purchase Agreement). Such Investor agrees
that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction
or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent
disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein (or in any other confidentiality
agreement between the Company and such Investor, if any) shall be deemed to limit any Investor’s ability to sell Registrable Securities
in a manner which is otherwise consistent with applicable laws and regulations.

 

    12 

     

    

 

(j)            The
Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure
of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary
to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required to be disclosed in such Registration
Statement pursuant to the 1933 Act, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable
order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to
the public other than by disclosure in violation of this Agreement or any other Transaction Document. The Company agrees that it shall,
upon learning that disclosure of such information concerning an Investor is sought in or by a court or governmental body of competent
jurisdiction or through other means, give prompt written notice to such Investor and allow such Investor, at such Investor’s expense,
to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

 

(k)            Without
limiting any obligation of the Company under the Securities Purchase Agreement, the Company shall use its best efforts either to (i) cause
all of the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities
of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted
under the rules of such exchange, (ii) secure designation and quotation of all of the Registrable Securities covered by each
Registration Statement on an Eligible Market (as defined in the Securities Purchase Agreement), or (iii) if, despite the Company’s
best efforts to satisfy the preceding clauses (i) or (ii) the Company is unsuccessful in satisfying the preceding clauses
(i) or (ii), without limiting the generality of the foregoing, to use its best efforts to arrange for at least two market makers
to register with the Financial Industry Regulatory Authority (“FINRA”) as such with respect to such Registrable Securities.
In addition, the Company shall cooperate with each Investor and any broker or dealer through which any such Investor proposes to sell
its Registrable Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested by such Investor. The Company
shall pay all fees and expenses in connection with satisfying its obligations under this Section 3(k).

 

(l)            The
Company shall cooperate with the Investors who hold Registrable Securities being offered and, to the extent applicable, facilitate the
timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered
pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts (as the case may be) as the
Investors may reasonably request from time to time and registered in such names as the Investors may request.

 

(m)            If
requested by an Investor, the Company shall as soon as practicable after receipt of notice from such Investor and subject to Section 3(r) hereof,
(i) incorporate in a prospectus supplement or post-effective amendment such information as an Investor reasonably requests to be
included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect
to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering
of the Registrable Securities to be sold in such offering; (ii) make all required filings of such prospectus supplement or post-effective
amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment; and (iii) supplement
or make amendments to any Registration Statement or prospectus contained therein if reasonably requested by an Investor holding any Registrable
Securities.

 

    13 

     

    

 

(n)            The
Company shall use its best efforts to cause the Registrable Securities covered by a Registration Statement to be registered with or approved
by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities.

 

(o)            The
Company shall make generally available to its security holders as soon as practical, but not later than ninety (90) days after the close
of the period covered thereby, an earnings statement (in form complying with, and in the manner provided by, the provisions of Rule 158
under the 1933 Act) covering a twelve-month period beginning not later than the first day of the Company’s fiscal quarter next
following the applicable Effective Date of each Registration Statement.

 

(p)            The
Company shall otherwise use its best efforts to comply with all applicable rules and regulations of the SEC in connection with any
registration hereunder.

 

(q)            Within
one (1) Business Day after a Registration Statement which covers Registrable Securities is declared effective by the SEC, the Company
shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with
copies to the Investors whose Registrable Securities are included in such Registration Statement) confirmation that such Registration
Statement has been declared effective by the SEC in the form attached hereto as Exhibit A.

 

(r)            Notwithstanding
anything to the contrary herein (but subject to the last sentence of this Section 3(r)), at any time after the Effective Date of
a particular Registration Statement, the Company may delay the disclosure of material, non-public information concerning the Company
or any of its Subsidiaries the disclosure of which at the time is not, in the good faith opinion of the board of directors of the Company,
in the best interest of the Company and, in the opinion of counsel to the Company, otherwise required (a “Grace Period”),
provided that the Company shall promptly notify the Investors in writing of the (i) existence of material, non-public information
giving rise to a Grace Period (provided that in each such notice the Company shall not disclose the content of such material, non-public
information to any of the Investors) and the date on which such Grace Period will begin and (ii) date on which such Grace Period
ends, provided further that (I) no Grace Period shall exceed ten (10) consecutive Trading Days and during any three hundred
sixty five (365) day period all such Grace Periods shall not exceed an aggregate of thirty (30) days, (II) the first day of any
Grace Period must be at least five (5) Trading Days after the last day of any prior Grace Period and (III) no Grace Period
may exist during the sixty (60) Trading Day period immediately following the Effective Date of such Registration Statement (provided
that such sixty (60) Trading Day period shall be extended by the number of Trading Days during such period and any extension thereof
contemplated by this proviso during which such Registration Statement is not effective or the prospectus contained therein is not available
for use) (each, an “Allowable Grace Period”). For purposes of determining the length of a Grace Period above, such
Grace Period shall begin on and include the date the Investors receive the notice referred to in clause (i) above and shall end
on and include the later of the date the Investors receive the notice referred to in clause (ii) above and the date referred to
in such notice. The provisions of Section 3(g) hereof shall not be applicable during the period of any Allowable Grace Period.
Upon expiration of each Grace Period, the Company shall again be bound by the first sentence of Section 3(f) with respect to
the information giving rise thereto unless such material, non-public information is no longer applicable. Notwithstanding anything to
the contrary contained in this Section 3(r), the Company shall cause its transfer agent to deliver unlegended shares of Common Stock
to a transferee of an Investor in accordance with the terms of the Securities Purchase Agreement in connection with any sale of Registrable
Securities with respect to which such Investor has entered into a contract for sale, and delivered a copy of the prospectus included
as part of the particular Registration Statement to the extent applicable, prior to such Investor’s receipt of the notice of a
Grace Period and for which the Investor has not yet settled.

 

    14 

     

    

 

(s)            The
Company shall take all other reasonable actions necessary to expedite and facilitate disposition by each Investors of its Registrable
Securities pursuant to each Registration Statement.

 

(t)            Neither
the Company nor any Subsidiary or affiliate thereof shall identify any Investor as an underwriter in any public disclosure or filing
with the SEC, the Principal Market or any Eligible Market and any Buyer being deemed an underwriter by the SEC shall not relieve the
Company of any obligations it has under this Agreement or any other Transaction Document (as defined in the Securities Purchase Agreement);
provided, however, that the foregoing shall not prohibit the Company from including the disclosure found in the "Plan of Distribution"
section attached hereto as Exhibit B in the Registration Statement.

 

(u)            Neither
the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after
the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights
granted to the Buyers in this Agreement or otherwise conflicts with the provisions hereof.

 

4.              Obligations
of the Investors.

 

(a)            At
least five (5) Business Days prior to the first anticipated filing date of each Registration Statement, the Company shall notify
each Investor in writing of the information the Company requires from each such Investor with respect to such Registration Statement.
It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect
to the Registrable Securities of a particular Investor that such Investor shall furnish to the Company such information regarding itself,
the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably
required to effect and maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents
in connection with such registration as the Company may reasonably request.

 

    15 

     

    

 

(b)            Each
Investor, by such Investor’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested
by the Company in connection with the preparation and filing of each Registration Statement hereunder, unless such Investor has notified
the Company in writing of such Investor’s election to exclude all of such Investor’s Registrable Securities from such Registration
Statement.

 

(c)            Each
Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(g) or
the first sentence of 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration
Statement(s) covering such Registrable Securities until such Investor’s receipt of the copies of the supplemented or amended
prospectus contemplated by Section 3(g) or the first sentence of Section 3(f) or receipt of notice that no supplement
or amendment is required. Notwithstanding anything to the contrary in this Section 4(c), the Company shall cause its transfer agent
to deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with the terms of the Securities Purchase Agreement
in connection with any sale of Registrable Securities with respect to which such Investor has entered into a contract for sale prior
to the Investor’s receipt of a notice from the Company of the happening of any event of the kind described in Section 3(g) or
the first sentence of Section 3(f) and for which such Investor has not yet settled.

 

5.              Expenses
of Registration.

 

All reasonable expenses,
other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2
and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, FINRA filing fees
(if any) and fees and disbursements of counsel for the Company shall be paid by the Company. The Company shall reimburse Legal Counsel
for its fees and disbursements in connection with registration, filing or qualification pursuant to Sections 2 and 3 of this Agreement
which amount shall be limited to $10,000 for each such registration, filing or qualification.

 

    16 

     

    

 

6.              Indemnification.

 

(a)            To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor and each of
its directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) and each Person,
if any, who controls such Investor within the meaning of the 1933 Act or the 1934 Act and each of the directors, officers, shareholders,
members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons (each, an “Indemnified
Person”), against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges,
costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts
paid in settlement or expenses, joint or several, (collectively, “Claims”) incurred in investigating, preparing or
defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental,
administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an Indemnified Person is or
may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or
actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement
or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing made
in connection with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction in
which Registrable Securities are offered (“Blue Sky Filing”), or the omission or alleged omission to state a material
fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged
untrue statement of a material fact contained in any preliminary prospectus if used prior to the effective date of such Registration
Statement, or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement
thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein,
in light of the circumstances under which the statements therein were made, not misleading or (iii) any violation or alleged violation
by the Company of the 1933 Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule or
regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to a Registration Statement or (iv) any
violation of this Agreement (the matters in the foregoing clauses (i) through (iv) being, collectively, “Violations”).
Subject to Section 6(c), the Company shall reimburse the Indemnified Persons, promptly as such expenses are incurred and are due
and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such
Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a):
(i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and
in conformity with information furnished in writing to the Company by such Indemnified Person for such Indemnified Person expressly for
use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, if such prospectus
was timely made available by the Company pursuant to Section 3(d); and (ii) shall not apply to amounts paid in settlement of
any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld
or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified
Person and shall survive the transfer of any of the Registrable Securities by any of the Investors pursuant to Section 9.

 

(b)            In
connection with any Registration Statement in which an Investor is participating, such Investor agrees to severally and not jointly indemnify,
hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors,
each of its officers who signs the Registration Statement and each Person, if any, who controls the Company within the meaning of the
1933 Act or the 1934 Act (each, an “Indemnified Party”), against any Claim or Indemnified Damages to which any of
them may become subject, under the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or
are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance upon and in
conformity with written information furnished to the Company by such Investor expressly for use in connection with such Registration
Statement; and, subject to Section 6(c) and the below provisos in this Section 6(b), such Investor will reimburse an Indemnified
Party any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such
Claim; provided, however, the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution
contained in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior
written consent of such Investor, which consent shall not be unreasonably withheld or delayed, provided further that such Investor shall
be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds
to such Investor as a result of the applicable sale of Registrable Securities pursuant to such Registration Statement. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive
the transfer of any of the Registrable Securities by any of the Investors pursuant to Section 9.

 

    17 

     

    

 

(c)            Promptly
after receipt by an Indemnified Person or Indemnified Party (as the case may be) under this Section 6 of notice of the commencement
of any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Indemnified
Person or Indemnified Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under
this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall
have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly
noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person
or the Indemnified Party (as the case may be); provided, however, an Indemnified Person or Indemnified Party (as the case may be) shall
have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying party if: (i) the
indemnifying party has agreed in writing to pay such fees and expenses; (ii) the indemnifying party shall have failed promptly to
assume the defense of such Claim and to employ counsel reasonably satisfactory to such Indemnified Person or Indemnified Party (as the
case may be) in any such Claim; or (iii) the named parties to any such Claim (including, without limitation, any impleaded parties)
include both such Indemnified Person or Indemnified Party (as the case may be) and the indemnifying party, and such Indemnified Person
or such Indemnified Party (as the case may be) shall have been advised by counsel that a conflict of interest is likely to exist if the
same counsel were to represent such Indemnified Person or such Indemnified Party and the indemnifying party (in which case, if such Indemnified
Person or such Indemnified Party (as the case may be) notifies the indemnifying party in writing that it elects to employ separate counsel
at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof and such
counsel shall be at the expense of the indemnifying party, provided further that in the case of clause (iii) above the indemnifying
party shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for such Indemnified
Person or Indemnified Party (as the case may be). The Indemnified
Party or Indemnified Person (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation
or defense of any such action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably
available to the Indemnified Party or Indemnified Person (as the case may be) which relates to such action or Claim. The indemnifying
party shall keep the Indemnified Party or Indemnified Person (as the case may be) reasonably apprised at all times as to the status of
the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action,
claim or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably withhold,
delay or condition its consent. No indemnifying party shall, without the prior written consent of the Indemnified Party or Indemnified
Person (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified Person (as the case
may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include any admission as
to fault on the part of the Indemnified Party. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated
to all rights of the Indemnified Party or Indemnified Person (as the case may be) with respect to all third parties, firms or corporations
relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within
a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified
Person or Indemnified Party (as the case may be) under this Section 6, except to the extent that the indemnifying party is materially
and adversely prejudiced in its ability to defend such action.

 

    18 

     

    

 

(d)            The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.

 

(e)            The
indemnity and contribution agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified
Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.

 

7.              Contribution.

 

To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however:
(i) no contribution shall be made under circumstances where the maker would not have been liable for indemnification under the fault
standards set forth in Section 6 of this Agreement, (ii) no Person involved in the sale of Registrable Securities which Person
is guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) in connection with such sale
shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (iii) contribution by any seller of Registrable Securities shall be limited in amount to the amount of net proceeds received
by such seller from the applicable sale of such Registrable Securities pursuant to such Registration Statement. Notwithstanding the provisions
of this Section 7, no Investor shall be required to contribute, in the aggregate, any amount in excess of the amount by which the
net proceeds actually received by such Investor from the applicable sale of the Registrable Securities subject to the Claim exceeds the
amount of any damages that such Investor has otherwise been required to pay, or would otherwise be required to pay under Section 6(b),
by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

    19 

     

    

 

8.              Reports
Under the 1934 Act.

 

With a view to making available
to the Investors the benefits of Rule 144, the Company agrees to:

 

(a)            make
and keep public information available, as those terms are understood and defined in Rule 144;

 

(b)            file
with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so long as
the Company remains subject to such requirements (it being understood and agreed that nothing herein shall limit any obligations of the
Company under the Securities Purchase Agreement) and the filing of such reports and other documents is required for the applicable provisions
of Rule 144; and

 

(c)            furnish
to each Investor so long as such Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company,
if true, that it has complied with the reporting, submission and posting requirements of Rule 144, the 1933 Act and the 1934 Act,
(ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company
with the SEC if such reports are not publicly available via EDGAR, and (iii) such other information as may be reasonably requested
to permit the Investors to sell such securities pursuant to Rule 144 without registration.

 

9.            Assignment
of Registration Rights.

 

All or any portion of the
rights under this Agreement shall be automatically assignable by each Investor to any transferee or assignee (as the case may be) of
all or any portion of such Investor’s Registrable Securities, Preferred Shares or Warrants if: (i) such Investor agrees in
writing with such transferee or assignee (as the case may be) to assign all or any portion of such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such transfer or assignment (as the case may be); (ii) the Company is,
within a reasonable time after such transfer or assignment (as the case may be), furnished with written notice of (a) the name and
address of such transferee or assignee (as the case may be), and (b) the securities with respect to which such registration rights
are being transferred or assigned (as the case may be); (iii) immediately following such transfer or assignment (as the case may
be) the further disposition of such securities by such transferee or assignee (as the case may be) is restricted under the 1933 Act or
applicable state securities laws if so required; (iv) at or before the time the Company receives the written notice contemplated
by clause (ii) of this sentence such transferee or assignee (as the case may be) agrees in writing with the Company to be bound
by all of the provisions contained herein; (v) such transfer or assignment (as the case may be) shall have been made in accordance
with the applicable requirements of the Securities Purchase Agreement, the Preferred Shares and the Warrants (as the case may be); and
(vi) such transfer or assignment (as the case may be) shall have been conducted in accordance with all applicable federal and state
securities laws.

 

    20 

     

    

 

10.            Amendment
of Registration Rights.

 

Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively),
only with the written consent of the Company and the Required Holders; provided that any such amendment or waiver that complies with
the foregoing, but that disproportionately, materially and adversely affects the rights and obligations of any Investor relative to the
comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor.
Any amendment or waiver effected in accordance with this Section 10 shall be binding upon each Investor and the Company, provided
that no such amendment shall be effective to the extent that it (1) applies to less than all of the holders of Registrable Securities
or (2) imposes any obligation or liability on any Investor without such Investor’s prior written consent (which may be granted
or withheld in such Investor’s sole discretion). No waiver shall be effective unless it is in writing and signed by an authorized
representative of the waiving party. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of this Agreement unless the same consideration (other than the reimbursement of legal fees) also is offered to all
of the parties to this Agreement.

 

11.            Miscellaneous.

 

(a)            Solely
for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns, or is deemed to
own, of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons
with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from
such record owner of such Registrable Securities.

 

(b)            Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by electronic
mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party
does not receive an automatically generated message from the recipient’s email server that such e-mail could not be delivered to
such recipient); or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified,
in each case, properly addressed to the party to receive the same. The mailing addresses and e-mail addresses for such communications
shall be:

 

If to the Company:

 

Digital Health Acquisition Corp.

980 N Federal Hwy #304 

Boca Raton, FL 33432 

Attention: Scott Wolf, Chief Executive Officer 

E-mail: scott@sjwolf.com

 

    21 

     

    

 

With a copy (for informational purposes only) to:

 

Manatt, Phelps & Philips, LLP 

695 Town Center Dr. 

Costa Mesa, CA 92626 

Attention: Thomas Poletti, Veronica Lah 

E-mail: TPoletti@manatt.com; VLah@manatt.com

 

If to the Transfer Agent:

 

Continental Stock Transfer & Trust Company, LLC 

1 State Street 30th Floor 

New York, NY 10004-1561 

Attention: Keri-Ann Cuadros

E-Mail: kcuadros@continentalstock.com

 

If to Legal Counsel:

 

Kelley Drye & Warren LLP

3 World Trade Center

175 Greenwich Street

New York, NY 10007

Telephone: (212) 808-7540

Facsimile: (212) 808-7897

Attention: Michael A. Adelstein, Esq.

E-mail: madelstein@kelleydrye.com

 

If to a Buyer, to its mailing address and/or
email address set forth on the Schedule of Buyers attached to the Securities Purchase Agreement, with copies to such Buyer’s representatives
as set forth on the Schedule of Buyers, or to such other mailing address and/or email address and/or to the attention of such other Person
as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such
change, provided that Kelley Drye & Warren LLP shall only be provided notices sent to the lead investor. Written confirmation
of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender’s e-mail containing the time, date and recipient’s e-mail or (C) provided by a courier or overnight
courier service shall be rebuttable evidence of personal service, receipt by e-mail or receipt from a nationally recognized overnight
delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(c)            Failure
of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
shall not operate as a waiver thereof. The Company and each Investor acknowledge and agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.
It is accordingly agreed that each party hereto shall be entitled to an injunction or injunctions to prevent or cure breaches of the
provisions of this Agreement by any other party hereto and to enforce specifically the terms and provisions hereof (without the necessity
of showing economic loss and without any bond or other security being required), this being in addition to any other remedy to which
any party may be entitled by law or equity.

 

    22 

     

    

 

(d)            All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New
York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New
York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process
and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for
such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(e)            If
any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction,
the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that
it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining
provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions
of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in
question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization
of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the
prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that
of the prohibited, invalid or unenforceable provision(s).

 

(f)            This
Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein
and therein constitute the entire agreement among the parties hereto and thereto solely with respect to the subject matter hereof and
thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein.
This Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced
herein and therein supersede all prior agreements and understandings among the parties hereto solely with respect to the subject matter
hereof and thereof; provided, however, nothing contained in this Agreement or any other Transaction Document shall (or shall be deemed
to) (i) have any effect on any agreements any Investor has entered into with the Company or any of its Subsidiaries prior to the
date hereof with respect to any prior investment made by such Investor in the Company, (ii) waive, alter, modify or amend in any
respect any obligations of the Company or any of its Subsidiaries or any rights of or benefits to any Investor or any other Person in
any agreement entered into prior to the date hereof between or among the Company and/or any of its Subsidiaries and any Investor and
all such agreements shall continue in full force and effect or (iii) limit any obligations of the Company under any of the other
Transaction Documents.

 

    23 

     

    

 

(g)            Subject
to compliance with Section 9 (if applicable), this Agreement shall inure to the benefit of and be binding upon the permitted successors
and assigns of each of the parties hereto. This Agreement is not for the benefit of, nor may any provision hereof be enforced by, any
Person, other than the parties hereto, their respective permitted successors and assigns and the Persons referred to in Sections 6
and 7 hereof.

 

(h)            The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless the
context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural
forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed
broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof”
and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

(i)            This
Agreement may be executed in two or more identical counterparts, each of which shall be deemed an original, but all of which shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the
other party. In the event that any signature is delivered by facsimile transmission or by an email which contains a portable document
format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

(j)            Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k)            The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of
strict construction will be applied against any party. Notwithstanding anything to the contrary set forth in Section 10, terms used
in this Agreement but defined in the other Transaction Documents shall have the meanings ascribed to such terms on the Closing Date in
such other Transaction Documents unless otherwise consented to in writing by each Investor.

 

    24 

     

    

 

(l)            All
consents and other determinations required to be made by the Investors pursuant to this Agreement shall be made, unless otherwise specified
in this Agreement, by the Required Holders, determined as if all of the outstanding Preferred Shares then held by the Investors have
been converted for Registrable Securities without regard to any limitations on redemption, amortization and/or conversion of the Preferred
Shares and the outstanding Warrants then held by Investors have been exercised for Registrable Securities without regard to any limitations
on exercise of the Warrants.

 

(m)            This
Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person.

 

(n)            The
obligations of each Investor under this Agreement and the other Transaction Documents are several and not joint with the obligations
of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under
this Agreement or any other Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken
by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors
do not so constitute, a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that
the Investors are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Investors are not acting in concert or as a group,
and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by this Agreement
or any of the other the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including,
without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary
for any other Investor to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect
to the obligations of the Company contained herein was solely in the control of the Company, not the action or decision of any Investor,
and was done solely for the convenience of the Company and not because it was required or requested to do so by any Investor. It is expressly
understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and
an Investor, solely, and not between the Company and the Investors collectively and not between and among Investors.

 

[signature page follows]

 

    25 

     

    

 

IN WITNESS WHEREOF, each Buyer and the
Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first
written above.

 

	 	COMPANY:
	 	 
	 	VSee Health, Inc. (f/k/a
    Digital Health Acquisition Corp.)
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
     

 

[Signature Page to Registration
Rights Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, each Buyer and the
Company have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first
written above.

 

	 	BUYERS:
	 	 
	 	3i, LP
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
     

 

 

[Signature Page to Registration Rights
Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.

 

	 	NOMIS BAY LTD.
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
     

 

[Signature Page to Registration Rights
Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Registration Rights Agreement to be duly executed
as of the date first written above.

 

	 	BPY LIMITED
	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
     

 

[Signature Page to Registration Rights
Agreement]

 

     

     

    

 

EXHIBIT A

 

FORM OF NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT

 

______________________

______________________

______________________

Attention: _____________

 

		Re:	Digital Health
                                            Acquisition Corp.

 

Ladies and Gentlemen:

 

[We are][I am] counsel to Digital
Health Acquisition Corp., a Delaware corporation (the “Company”), and have represented the Company in connection with
that certain Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into by and among the Company
and the buyers named therein (collectively, the “Holders”) pursuant to which the Company issued to the Holders series
A convertible preferred stock (the “Preferred Shares”) convertible into the Company’s shares of common stock,
$0.001 par value per share (the “Common Stock”), and warrants exercisable for shares of Common Stock (the “Warrants”).
Pursuant to the Securities Purchase Agreement, the Company also has entered into a Registration Rights Agreement with the Holders (the
 “Registration Rights Agreement”) pursuant to which the Company agreed, among other things, to register the Registrable
Securities (as defined in the Registration Rights Agreement), including the shares of Common Stock issuable upon conversion of the Preferred
Shares and exercise of the Warrants, under the Securities Act of 1933, as amended (the “1933 Act”). In connection
with the Company’s obligations under the Registration Rights Agreement, on ____________ ___, 20__, the Company filed a Registration
Statement on Form [S-1][S-3] (File No. 333-_____________) (the “Registration Statement”) with the Securities
and Exchange Commission (the “SEC”) relating to the Registrable Securities which names each of the Holders as a selling
stockholder thereunder.

 

In connection with the foregoing,
[we][I] advise you that [a member of the SEC’s staff has advised [us][me] by telephone that [the SEC has entered an order declaring
the Registration Statement effective under the 1933 Act at [ENTER TIME OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS]] [an order
declaring the Registration Statement effective under the 1933 Act at [ENTER TIME OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS]]
has been posted on the web site of the SEC at www.sec.gov] and [we][I] have no knowledge, after a review of information posted on the
website of the SEC at http://www.sec.gov/litigation/stoporders.shtml, that any stop order suspending its effectiveness has been issued
or that any proceedings for that purpose are pending before, or threatened by, the SEC and the Registrable Securities are available for
resale under the 1933 Act pursuant to the Registration Statement.

 

     

     

    

 

This letter shall serve as
our standing opinion to you that the shares of Common Stock underlying the Preferred Shares and Warrants are freely transferable by the
Holders pursuant to the Registration Statement. You need not require further letters from us to effect any future legend-free issuance
or reissuance of such shares of Common Stock to the Holders as contemplated by the Company’s Irrevocable Transfer Agent Instructions
dated _________ __, 20__.

 

	 	Very truly yours,

     

    [ISSUER’S COUNSEL]

    

    
	 	 
	 	By:	            

 

	CC:	3i, LP
	 	[OTHER BUYERS]

 

     

     

    

 

EXHIBIT B

 

SELLING STOCKHOLDERS

 

The shares of common stock
being offered by the selling stockholders are those issuable to the selling stockholders upon conversion of the preferred shares and
exercise of the warrants. For additional information regarding the issuance of the preferred shares and the warrants, see “Private
Placement of Preferred Shares” above. We are registering the shares of common stock in order to permit the selling stockholders
to offer the shares for resale from time to time. Except for the ownership of the preferred shares and the warrants issued pursuant to
the Securities Purchase Agreement, the selling stockholders have not had any material relationship with us within the past three years.

 

The table below lists the
selling stockholders and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities
Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of common stock held by each of the selling
stockholders. The second column lists the number of shares of common stock beneficially owned by the selling stockholders, based on their
respective ownership of shares of common stock, preferred shares and warrants, as of ________, 2022, assuming conversion of the preferred
shares and exercise of the warrants held by each such selling stockholder on that date but taking account of any limitations on conversion
and exercise set forth therein.

 

The third column lists the
shares of common stock being offered by this prospectus by the selling stockholders and does not take in account any limitations on (i) conversion
of the preferred shares set forth therein or (ii) exercise of the warrants set forth therein.

 

In accordance with the terms
of a registration rights agreement with the holders of the preferred shares and the warrants, this prospectus generally covers the resale
of 200% of the sum of (i) the maximum number of shares of common stock issued or issuable pursuant to certificate of designations,
and (ii) the maximum number of shares of common stock issued or issuable upon exercise of the warrants, in each case, determined
as if the outstanding preferred shares (including dividends on the preferred shares through [DATE]) and warrants were converted or exercised
(as the case may be) in full (without regard to any limitations on conversion or exercise contained therein solely for the purpose of
such calculation) at a conversion price equal to $[      ], the floor price of the preferred shares, or an exercise price calculated as of
the trading day immediately preceding the date this registration statement was initially filed with the SEC. Because the conversion price
and the floor price of the preferred shares and the exercise price of the warrants may be adjusted, the number of shares that will actually
be issued may be more or less than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of
the shares offered by the selling stockholders pursuant to this prospectus.

 

Under the terms of the preferred
shares and the warrants, a selling stockholder may not convert the preferred shares or exercise the warrants to the extent (but only
to the extent) such selling stockholder or any of its affiliates would beneficially own a number of shares of our common stock which
would exceed 4.99% of the outstanding shares of the Company. The number of shares in the second column reflects these limitations. The
selling stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

 

     

     

    

 

	

    Name of Selling Stockholder

    	Number
    of Shares of 

    Common Stock Owned

    Prior to Offering	Maximum
    Number of Shares

    of Common Stock to be Sold

    Pursuant to this Prospectus	Number
    of Shares of

    Common Stock of 

    Owned After Offering
	 	 	 	 
	

    3i, LP (1)	 	 	 
	[OTHER BUYERS]	 	 	 
	 	 	 	 

		(1)	[              ]

 

     

     

    

 

PLAN OF DISTRIBUTION

 

We are registering the shares
of common stock issuable upon conversion of the preferred shares and exercise of the warrants to permit the resale of these shares of
common stock by the holders of the preferred shares and warrants from time to time after the date of this prospectus. We will not receive
any of the proceeds from the sale by the selling stockholders of the shares of common stock, although we will receive the exercise price
of any Warrants not exercised by the selling stockholders on a cashless exercise basis. We will bear all fees and expenses incident to
our obligation to register the shares of common stock.

 

The selling stockholders
may sell all or a portion of the shares of common stock held by them and offered hereby from time to time directly or through one or
more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling
stockholders will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of common stock may
be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,
pursuant to one or more of the following methods:

 

		·	on
                                            any national securities exchange or quotation service on which the securities may be listed
                                            or quoted at the time of sale;

 

		·	in
                                            the over-the-counter market;

 

		·	in
                                            transactions otherwise than on these exchanges or systems or in the over-the-counter market;

 

		·	through
                                            the writing or settlement of options, whether such options are listed on an options exchange
                                            or otherwise;

 

		·	ordinary
                                            brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		·	block
                                            trades in which the broker-dealer will attempt to sell the shares as agent but may position
                                            and resell a portion of the block as principal to facilitate the transaction;

 

		·	purchases
                                            by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		·	an
                                            exchange distribution in accordance with the rules of the applicable exchange;

 

		·	privately
                                            negotiated transactions;

 

		·	short
                                            sales made after the date the Registration Statement is declared effective by the SEC;

 

     

     

    

 

		·	broker-dealers
                                            may agree with a selling security holder to sell a specified number of such shares at a stipulated
                                            price per share;

 

		·	a
                                            combination of any such methods of sale; and

 

		·	any
                                            other method permitted pursuant to applicable law.

 

The selling stockholders
may also sell shares of common stock under Rule 144 promulgated under the Securities Act of 1933, as amended, if available, rather
than under this prospectus. In addition, the selling stockholders may transfer the shares of common stock by other means not described
in this prospectus. If the selling stockholders effect such transactions by selling shares of common stock to or through underwriters,
broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or
commissions from the selling stockholders or commissions from purchasers of the shares of common stock for whom they may act as agent
or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents
may be in excess of those customary in the types of transactions involved). In connection with sales of the shares of common stock or
otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales
of the shares of common stock in the course of hedging in positions they assume. The selling stockholders may also sell shares of common
stock short and deliver shares of common stock covered by this prospectus to close out short positions and to return borrowed shares
in connection with such short sales. The selling stockholders may also loan or pledge shares of common stock to broker-dealers that in
turn may sell such shares.

 

The selling stockholders
may pledge or grant a security interest in some or all of the preferred shares, warrants or shares of common stock owned by them and,
if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common
stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable
provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares
of common stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.

 

To the extent required by
the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealer participating in the
distribution of the shares of common stock may be deemed to be “underwriters” within the meaning of the Securities Act, and
any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions
or discounts under the Securities Act. At the time a particular offering of the shares of common stock is made, a prospectus supplement,
if required, will be distributed, which will set forth the aggregate amount of shares of common stock being offered and the terms of
the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation
from the selling stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.

 

     

     

    

 

Under the securities laws
of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition,
in some states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state
or an exemption from registration or qualification is available and is complied with.

 

There can be no assurance
that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of
which this prospectus forms a part.

 

The selling stockholders
and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934,
as amended, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M
of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock by the selling stockholders
and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the
distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the
foregoing may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making
activities with respect to the shares of common stock.

 

We will pay all expenses
of the registration of the shares of common stock pursuant to the registration rights agreement, estimated to be $[     ]
in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities
or “blue sky” laws; provided, however, a selling stockholder will pay all underwriting discounts and selling commissions,
if any. We will indemnify the selling stockholders against liabilities, including some liabilities under the Securities Act in accordance
with the registration rights agreements or the selling stockholders will be entitled to contribution. We may be indemnified by the selling
stockholders against civil liabilities, including liabilities under the Securities Act that may arise from any written information furnished
to us by the selling stockholder specifically for use in this prospectus, in accordance with the related registration rights agreements
or we may be entitled to contribution.

 

Once sold under the registration
statement, of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons other than
our affiliates.Exhibit 10.5

 

SECOND AMENDED AND RESTATED TRANSACTION SUPPORT
AGREEMENT

 

This SECOND AMENDED AND
RESTATED TRANSACTION SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 6, 2022, by and among
Digital Health Acquisition Corp., a Delaware corporation (“Digital Health”), Milton Chen (“Chen”),
Dr. Imoigele Aisiku (“Aisiku”), and the undersigned parties listed under Stockholders on the signature page(s) hereto
(the “Stockholders”). Each of Digital Health, Chen, Aisiku and each of the Stockholders are sometimes referred to herein
individually as a “Party” and collectively as the “Parties”. Capitalized terms used but not otherwise
defined herein shall have the meanings ascribed to them in the Business Combination Agreement (defined below).

 

RECITALS

 

WHEREAS,
on June 15, 2022, Digital Health, DHAC Merger Sub I, Inc., a Delaware corporation (“Merger Sub I”), DHAC
Merger Sub II, Inc., a Texas corporation (“Merger Sub II”), VSee Lab, Inc., a Delaware corporation (“VSee”),
and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”) (iDoc and VSee are each, a “Company”
and, are collectively, the “Companies”), entered into that certain Business Combination Agreement, as amended by the
Amended and Restated Business Combination Agreement, dated August 9, 2022, by and among Digital Health, Merger Sub I, Merger Sub
II, and the Companies (as amended to date, and as amended, supplemented or otherwise modified from time to time in accordance with its
terms, the “Original Business Combination Agreement”) pursuant to which, among other things, Merger Sub I will merge
with and into VSee and Merger Sub II will merge with and into iDoc, with each of VSee and iDoc as the surviving company in their respective
mergers and, after giving effect to such mergers, becoming wholly-owned Subsidiaries of Digital Health, in each case, on the terms and
subject to the conditions set forth in the Business Combination Agreement;

 

WHEREAS,
in connection with the Original Business Combination Agreement, Digital Health, Chen, Aisiku, and certain Stockholders entered into the
Transaction Support Agreement, dated June 15, 2022, as amended by the Amended and Restated Transaction Support Agreement, dated August 9,
2022 (as amended, the “Original Transaction Support Agreement”);

 

WHEREAS,
the parties to the Original Business Combination Agreement desire to amend and restate the Original Business Combination Agreement in
its entirety pursuant to the Second Amended and Restated Business Combination Agreement (as amended and restated, together with all exhibits
and schedules thereto, the “Business Combination Agreement”), to be entered into by and among the parties to the Original
Business Combination Agreement, in order to amend the terms of consideration paid to the parties thereto and in connection therewith;

 

WHEREAS,
the parties hereto desire to amend and restate the Original Transaction Support Agreement pursuant to the terms of this Agreement, which
shall replace the Original Transaction Support Agreement in its entirety;

 

WHEREAS,
Chen is the Executive Vice Chairman of the Board of Directors of VSee and Aisiku is the Executive Chairman of the Board of Directors of
iDoc;

 

WHEREAS,
each Stockholder is the record and beneficial owner of the number of shares of VSee Stock and iDoc Stock set forth opposite such Stockholder’s
name on Schedule A hereto (together with any other Equity Securities of either Company that such Stockholder acquires
record or beneficial ownership of after the date hereof, collectively, the “Subject Shares”);

 

WHEREAS,
in consideration for the benefits to be received by Chen, Aisiku, and the Stockholders under the terms of the Business Combination Agreement
and as a material inducement to Digital Health and the other Parent Parties agreeing to enter into and consummate the transactions contemplated
by the Business Combination Agreement, the Stockholders, Chen, and Aisiku agree to enter into this Agreement and to be bound by the agreements,
covenants and obligations contained in this Agreement; and

 

     

     

    

 

WHEREAS,
the Parties acknowledge and agree that Digital Health and the other Parent Parties would not have entered into and agreed to consummate
the transactions contemplated by the Business Combination Agreement without the Stockholders, Chen, and Aisiku entering into this Agreement
and agreeing to be bound by the agreements, covenants and obligations contained in this Agreement.

 

NOW,
THEREFORE, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows:

 

AGREEMENT

 

1.            Company
Stockholder Written Consents and Related Matters.

 

(a)            As
promptly as reasonably practicable (and in any event within two (2) Business Days) following the time at which the Registration Statement
/ Proxy Statement is declared effective under the Securities Act, the Stockholders shall duly execute and deliver to the Companies
and Digital Health the Company Party Stockholder Written Consents (in such form as each Stockholder may reasonably approve) under which
they shall irrevocably and unconditionally consent to the matters, actions and proposals contemplated by Section 5.13(b) of
the Business Combination Agreement. Without limiting the generality of the first sentence of this Section 1(a), prior to the
Closing, the Stockholders shall vote (or cause to be voted) the Subject Shares against and withhold consent with respect to (A) any
Company Acquisition Proposal or (B) any other matter, action or proposal that would reasonably be expected to result in (x) a
breach of any of either Company’s covenants, agreements or obligations under the Business Combination Agreement or (y) any
of the conditions to the Closing set forth in Sections 6.1 or 6.2 of the Business Combination Agreement not being satisfied.

 

(b)            Without
limiting any other rights or remedies of Digital Health, each Stockholder hereby irrevocably appoints Digital Health or any individual
designated by Digital Health as such Stockholder’s agent, attorney-in-fact and proxy (with full power of substitution and resubstituting),
for and in the name, place and stead of such Stockholder, to attend on behalf of such Stockholder any meeting of the Company Parties Stockholders
with respect to the matters described in Section 1(a), to include such Stockholder’s Subject Shares in any computation
for purposes of establishing a quorum at any such meeting of the applicable Company Parties Stockholders, to vote (or cause to be voted)
such Stockholder’s Subject Shares or consent (or withhold consent) with respect to any of the matters described in Section 1(a) in
connection with any meeting of the applicable Company Parties Stockholders or any action by written consent by the applicable Company
Parties Stockholders (including the Company Stockholder Written Consents), in each case, only in the event that such Stockholder fails
to perform or otherwise comply with the covenants, agreements or obligations set forth in Section 1(a).

 

(c)            The
proxy granted by each Stockholder pursuant to Section 1(b) is coupled with an interest sufficient at law to support an
irrevocable proxy and is granted in consideration for Digital Health entering into the Business Combination Agreement and agreeing to
consummate the transactions contemplated thereby. Subject to Section 5 hereof, the proxy granted by each Stockholder pursuant to Section 1(b) is
also a durable proxy and shall survive the bankruptcy, dissolution, death, incapacity or other inability to act by such Stockholder and
shall revoke any and all prior proxies granted by such Stockholder with respect to its Subject Shares. The vote or consent of the proxyholder
in accordance with Section 1(b) and with respect to the matters in Section 1(a) shall control in the event
of any conflict between such vote or consent by the proxyholder of the Subject Shares and a vote or consent by a Stockholder of the Subject
Shares (or any other Person with the power to vote the Subject Shares) with respect to the matters in Section 1(a). The proxyholder
may not exercise the proxy granted pursuant to Section 1(b) on any matter except those provided in Section 1(a) and
only in the event that such Stockholder fails to perform or otherwise comply with the covenants, agreements or obligations set forth in
Section 1(a). For the avoidance of doubt, the Stockholder may vote the Subject Shares on all other matters, subject to, for the avoidance
of doubt, the other applicable covenants, agreements and obligations set forth in this Agreement.

 

     

     

    

 

(d)            Each
Stockholder hereby irrevocably and unconditionally waives and agrees not to exercise or assert, or make any demand in respect of, any
rights of appraisal, any dissenters’ rights and any similar rights relating to the Mergers or any other transaction contemplated
by the Business Combination Agreement that the Stockholder may have (under Section 262 of General Corporation Law of the State of
Delaware, under Section 21.460 of the Business Organizations Code of the State of Texas or otherwise) by virtue of, or with respect
to, any outstanding Subject Shares owned of record or beneficially by the Stockholder.

 

2.            Other
Covenants and Agreements.

 

(a)            Subject
to Section 2(c), each Stockholder shall be bound by and subject to Section 5.3(a) (Confidentiality) and Section 5.4(a) (Public
Announcements) of the Business Combination Agreement to the same extent as such provisions apply to the parties to the Business Combination
Agreement, as if such Stockholder were directly party thereto, and each Stockholder, Chen and Aisiku shall be bound by and subject to
the first sentence of Section 5.6(a) (Exclusive Dealing) and Section 9.17 (Trust Account Waiver) of the Business Combination
Agreement to the same extent as such provisions apply to the Companies, as if such Stockholder were directly party thereto. Each of Chen
and Aisiku shall, in their respective capacities as Executive Vice Chairman of the Board of Directors of VSee and Executive Chairman of
the Board of Directors of iDoc, respectively, cause to be done such further acts and things as may be reasonably necessary or advisable
to cause the Companies to fulfill its obligations under the Business Combination Agreement and consummate the transactions contemplated
thereby.

 

(b)            Each
Stockholder, Chen, and Aisiku acknowledges and agrees that Digital Health and the other Parent Parties are entering into the Business
Combination Agreement in reliance upon such Stockholder entering into this Agreement and agreeing to be bound by, and perform, or otherwise
comply with, as applicable, the agreements, covenants and obligations contained in this Agreement and but for such Stockholder, Chen,
and Aisiku entering into this Agreement and agreeing to be bound by, and perform, or otherwise comply with, as applicable, the agreements,
covenants and obligations contained in this Agreement, Digital Health and the other Parent Parties would not have entered into or agreed
to consummate the transactions contemplated by the Business Combination Agreement.

 

(c)            Notwithstanding
Section 2(a), (i) Salesforce, Inc. shall not be bound by the Mutual Non-Disclosure Agreement, dated as of November 11,
2021, by and between Digital Health and iDoc, (ii) Salesforce, Inc. shall not be bound by Section 5 of the Mutual Non-Disclosure
Agreement, dated as of November 11, 2021, by and between Digital Health and VSee (the “VSee Confidentiality Agreement”),
and (iii) Section 5.3(a) (Confidentiality) of the Business Combination Agreement and all provisions of the VSee Confidentiality
Agreement shall cease to apply to Salesforce, Inc. on November 11, 2023.

 

(d)            Salesforce, Inc.
is aware, and will advise its Representatives who receive any Information (as defined in the VSee Confidentiality Agreement), of the restrictions
imposed by the Securities Laws (as defined in the VSee Confidentiality Agreement) on the purchase or sale of securities by any Person
who has received material, non-public information from the issuer of such securities and on the communication of such information to any
other Person when it is reasonably foreseeable that such other Person is likely to purchase or sell such securities in reliance upon such
information.

 

     

     

    

 

3.            Stockholder
Representations and Warranties. Each of the Stockholders, Chen, and Aisiku represents and warrants to Digital Health, on behalf
of him or itself, as follows:

 

(a)            To
the extent such Stockholder is an entity, such Stockholder is a limited liability company, trust or other applicable entity duly organized
or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect
to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of formation
or organization (as applicable).

 

(b)            Such
Stockholder has the requisite limited liability company, trust or other similar power and authority to execute and deliver this Agreement,
to perform its covenants, agreements and obligations hereunder (including, for the avoidance of doubt, those covenants, agreements and
obligations hereunder that relate to the provisions of the Business Combination Agreement), and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement has been duly authorized by all necessary limited liability company, trust or other
similar action on the part of such Stockholder. This Agreement has been duly and validly executed and delivered by the Stockholders, Chen,
and Aisiku and constitutes a valid, legal and binding agreement of each Stockholder, Chen, and Aisiku (assuming that this Agreement is
duly authorized, executed and delivered by Digital Health), enforceable against each Stockholder, Chen, and Aisiku in accordance with
its terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement
of creditors’ rights and subject to general principles of equity).

 

(c)            No
consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity is required on the part of
any Stockholder, Chen, or Aisiku with respect to such Stockholder’s, Chen’s, or Aisiku’s execution, delivery or performance
of its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements and
obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions
contemplated hereby, except for any consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of
which would not adversely affect the ability of the Stockholders, Chen, or Aisiku to perform, or otherwise comply with, any of its covenants,
agreements or obligations hereunder in any material respect.

 

(d)            None
of the execution or delivery of this Agreement by the Stockholders, Chen, and Aisiku, the performance by the Stockholders, Chen, and Aisiku
of any of its covenants, agreements or obligations under this Agreement (including, for the avoidance of doubt, those covenants, agreements
and obligations under this Agreement that relate to the provisions of the Business Combination Agreement) or the consummation of the transactions
contemplated hereby will, directly or indirectly (with or without due notice or lapse of time or both) (i) result in any breach of
any provision of any Stockholder’s Governing Documents, (ii) result in a violation or breach of, or constitute a default or
give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any
of the terms, conditions or provisions of any Contract to which any Stockholder, Chen, or Aisiku is a party, (iii) violate, or constitute
a breach under, any Order or applicable Law to which Chen, Aisiku, any Stockholder or any of their respective properties or assets is
bound or (iv) result in the creation of any Lien upon the Subject Shares, except, in the case of any of clauses (ii) and (iii) above,
as would not adversely affect the ability of the Stockholders, Chen, or Aisiku to perform, or otherwise comply with, any of its covenants,
agreements or obligations hereunder in any material respect.

 

     

     

    

 

(e)            Such
Stockholder is the record and beneficial owner of its Subject Shares, free and clear of all Liens (other than transfer restrictions under
applicable Securities Law or under the Company Parties Stockholders Agreements). Except for the Equity Securities of the Companies set
forth on Schedule A hereto with respect to such Stockholder, together with any other Equity Securities of the Companies that
such Stockholder acquires record or beneficial ownership of after the date hereof that is either permitted pursuant to, or acquired in
accordance with, Section 5.1(b)(iv) of the Business Combination Agreement, such Stockholder does not own, beneficially or of
record, any Equity Securities of any Group Company. Except as otherwise expressly contemplated by the Company Parties Stockholders Agreements,
or any other agreement existing on the date hereof and made available to Digital Health or that is entered into in accordance with the
Business Combination Agreement, such Stockholder has no right to acquire any Equity Securities of any Group Companies. Such Stockholder
has the sole right to vote (and provide consent in respect of, as applicable) the Subject Shares and, except for this Agreement and the
Business Combination Agreement, Company Parties Stockholders Agreements, BCA Lock-up Agreements and any Contract with respect to a Permitted
Transfer such Stockholder is not party to or bound by (i) any option, warrant, purchase right, or other Contract that would (either
alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent))
require such Stockholder to Transfer any of its Subject Shares or (ii) any voting trust, proxy or other Contract with respect to
the voting or Transfer of any of its Subject Shares.

 

(f)            There
is no Proceeding pending or, to Chen’s, Aisiku’s or such Stockholder’s knowledge, threatened against Chen, Aisiku, or
such Stockholder that, if adversely decided or resolved, would reasonably be expected to prevent Chen, Aisiku, or such Stockholder from
performing, or otherwise complying with, any of its covenants, agreements or obligations under this Agreement in any material respect.

 

(g)            Each
of Chen, Aisiku, and such Stockholder, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and
agrees that (i) it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment
concerning, the business, assets, condition, operations and prospects of, the Parent Parties and (ii) it has been furnished with
or given access to such documents and information about the Parent Parties and their respective businesses and operations as it and its
Representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and performance
of this Agreement, the other Ancillary Documents to which it is or will be a party and the transactions contemplated hereby and thereby.

 

(h)            In
entering into this Agreement and the other Ancillary Documents to which he or it is or will be a party, Chen, Aisiku, and such Stockholder
has relied solely on his or its own investigation and analysis and the representations and warranties expressly set forth in the Ancillary
Documents to which he or it is or will be a party and no other representations or warranties of any Parent Party (including, for the avoidance
of doubt, none of the representations or warranties of any Parent Party set forth in the Business Combination Agreement or any other Ancillary
Document), any Parent Non-Party Affiliate or any other Person, either express or implied, and each of Chen, Aisiku, and such Stockholder,
on his or its own behalf and on behalf of his or its Representatives, acknowledges, represents, warrants and agrees that, except for the
representations and warranties expressly set forth in the Ancillary Documents to which he or it is or will be a party, none of the Parent
Parties, any Parent Non-Party Affiliate or any other Person makes or has made any representation or warranty, either express or implied,
in connection with or related to this Agreement, the Ancillary Documents to which he or it is or will be a party or the transactions contemplated
hereby or thereby.

 

     

     

    

 

4.            Transfer
of Subject Securities. Except as expressly contemplated by the Business Combination Agreement, with the prior written consent
of Digital Health (such consent to be given or withheld in its sole discretion) or to a Permitted Transferee (as defined below), from
and after the date hereof, each Stockholder agrees not to (a) Transfer any of its Subject Shares, (b) enter into (i) any
option, warrant, purchase right, or other Contract that would (either alone or in connection with one or more events, developments or
events (including the satisfaction or waiver of any conditions precedent)) require such Stockholder to Transfer its Subject Shares or
(ii) any voting trust, proxy or other Contract with respect to the voting or Transfer of its Subject Shares, or (c) take any
actions in furtherance of any of the matters described in the foregoing clauses (a) or (b). For purposes of this Agreement,
 “Transfer” means any, direct or indirect, sale, transfer, assignment, pledge, mortgage, exchange, hypothecation, grant
of a security interest in or disposition or encumbrance of an interest (whether with or without consideration, whether voluntarily or
involuntarily or by operation of law or otherwise), and “Permitted Transferee” means (i) with respect to any specified
Person that is not a natural person, (a) any other Person which directly or indirectly through one or more intermediaries controls,
or is controlled by, or is under common control with, such specified Person, and (b) any corporation, trust, limited liability company,
general or limited partnership or other entity advised or managed by, or under common control or management with, such Person (for the
purposes of this definition, “control” (including, with correlative meanings, the terms “controlling,” “controlled
by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly,
of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities,
by agreement or otherwise) and (ii) with respect to any natural person, (x) a parent, spouse (but not including a former spouse
or a spouse from whom such Person is legally separated) or child (including those adopted) of such individual, and (y) each trustee,
solely in his or her capacity as trustee, for a trust naming only one or more of the Persons listed in sub-clause (x) as beneficiaries,
in each case, with respect to the applicable Stockholder, Chen or Aisiku, that delivers to Digital Health a notice by which he, she or
it agrees to be bound by all the obligations of the applicable Stockholder hereunder with respect to its Subject Shares upon a Transfer
of such Subject Shares to such Person.

 

5.            Termination.
This Agreement shall automatically terminate, without any notice or other action by any Party, and be void ab initio upon
the earlier of (a) the Effective Time; and (b) the termination of the Business Combination Agreement in accordance with its
terms. Upon termination of this Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further
obligations or Liabilities under, or with respect to, this Agreement and the proxy granted in Section 1(b) shall be terminated
in all respects. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i) the termination of this Agreement
pursuant to Section 5(b) shall not affect any Liability on the part of any Party for a Willful Breach of any covenant or
agreement set forth in this Agreement prior to such termination or fraud, (ii) the first sentence of Section 2(a) (solely
to the extent that it relates to Section 5.3(a) (Confidentiality) of the Business Combination Agreement) and the representations
and warranties set forth in Sections 3(g) and (h) shall each survive any termination of this Agreement, (iii) the
first sentence of Section 2(a) (solely to the extent that it relates to Section 5.4(a) (Public Announcements)
of the Business Combination Agreement) shall survive the termination of this Agreement pursuant to Section 5(a) and (iv) the
first sentence of Section 2(a) (solely to the extent that it relates to Section 9.17 (Trust Account Waiver) of the
Business Combination Agreement) shall survive the termination of this Agreement pursuant to Section 5(b). For purposes of this Section 5,
 “Willful Breach” means a material breach that is a consequence of an act undertaken or a failure to act by the breaching
Party with the knowledge that the taking of such act or such failure to act would, or would reasonably be expected to, constitute or result
in a breach of this Agreement.

 

6.            Fiduciary
Duties. Notwithstanding anything in this Agreement to the contrary, (a) no Stockholder makes any agreement or understanding
herein in any capacity other than in such Stockholder’s capacity as a record holder and beneficial owner of its Subject Shares and
not in any other capacity and (b) nothing herein will be construed to limit or affect any action or inaction by any representative
or Affiliate of such Stockholder serving as a member of the board of directors of any Group Company or as an officer, employee or fiduciary
of any Group Company, in each case, acting in such person’s capacity as a director, officer, employee or fiduciary of such Group
Company.

 

     

     

    

 

7.            No
Recourse. Except for claims pursuant to the Business Combination Agreement or any other Ancillary Document by any party(ies) thereto
against any other party(ies) thereto, each Party agrees that (a) this Agreement may be enforced only against, and any action for
breach of this Agreement may be made only against, the Parties, and no claims of any nature whatsoever (whether in tort, contract or otherwise)
arising under or relating to this Agreement, the negotiation hereof or its subject matter, or the transactions contemplated hereby shall
be asserted against either Company or any Company Non-Party Affiliate (other than Chen, Aisiku, or any Stockholder named as a party hereto,
on the terms and subject to the conditions set forth herein) or any Parent Non-Party Affiliate, and (b) none of the Companies, any
Company Non-Party Affiliates (other than Chen, Aisiku, or any Stockholder named as a party hereto, on the terms and subject to the conditions
set forth herein) or any Parent Non-Party Affiliate shall have any Liability arising out of or relating to this Agreement, the negotiation
hereof or its subject matter, or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract
or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection
herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions with respect to any information
or materials of any kind furnished in connection with this Agreement, the negotiation hereof or the transactions contemplated hereby.

 

8.            Notices.
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed
to have been duly given) by delivery in person, by facsimile (having obtained electronic delivery confirmation thereof) if applicable,
e-mail (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender that the email was sent to
the intended recipient thereof without an “error” or similar message that such email was not received by such intended recipient)),
or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to the other Parties as follows:

 

If to Digital Health, to:

 

c/o Digital Health Acquisition Corp.

980 N Federal Hwy #304

Boca Raton, FL 33432

Attention: Scott Wolf, Chief Executive Officer

E-mail: scott@sjwolf.com

 

with a copy (which shall not constitute notice)
to:

 

Manatt, Phelps & Philips, LLP

695 Town Center Dr.

Costa Mesa, CA 92626

Attention: Thomas Poletti, Veronica Lah

E-mail: TPoletti@manatt.com; VLah@manatt.com

 

If to any Stockholder, to such Stockholder’s address set forth
on Schedule A.

 

If to Chen, to:

 

c/o
VSee Lab, Inc.

3188 Kimlee Drive

San Jose, CA 95132

Attention: Milton Chen, CEO

Email: milton@vsee.com

 

     

     

    

 

with a copy (which shall not constitute notice) to:

 

Holcombe Law Group

12545 Oak Mist Lane

Auburn, CA 95602

Attention: Jessica Holcombe

E-mail: jholcombe@holcombelawgroup.com

 

If to Aisiku, to:

 

c/o
iDoc Virtual Telehealth Solutions, Inc.

2311 West Main Street

Houston, Texas 77098

Attention: Dr. Imoigele Aisiku, Chief Executive Officer

Email: iaisiku@idocvms.com

 

with a copy (which shall not constitute notice) to:

 

Pryor Cashman LLP

7 Times Square, 40th Floor

New York, NY 10036

Attention: M. Ali Panjwani and John Crowe

E-mail: ali.panjwani@pryorcashman.com; jcrowe@pryorcashman.com

 

or to such other address as the Party to whom
notice is given may have previously furnished to the others in writing in the manner set forth above.

 

9.            Entire
Agreement. This Agreement, the Business Combination Agreement and documents referred to herein and therein constitute the entire
agreement of the Parties with respect to the subject matter of this Agreement, and supersede all prior agreements and undertakings, both
written and oral, among the Parties with respect to the subject matter of this Agreement, except as otherwise expressly provided in this
Agreement.

 

10.          Amendments
and Waivers; Assignment. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is
in writing and signed by Chen, Aisiku, the Stockholders and Digital Health. Notwithstanding the foregoing, no failure or delay by any
Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise of any other right hereunder. Neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assignable by any Stockholder without Digital Health’s prior written consent (to be withheld or given in its sole discretion)
except to a Permitted Transferee to which Subject Shares are Transferred in accordance with the terms hereof.

 

11.          Fees
and Expenses. Except as otherwise expressly set forth in the Business Combination Agreement, all fees and expenses incurred in
connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements of counsel, financial advisors
and accountants, shall be paid by the Party incurring such fees or expenses.

 

     

     

    

 

12.          Remedies.
Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive of
any other remedy conferred hereby upon, or available at law or in equity to, such Party, and the exercise by a Party of any one remedy
will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available,
would not be an adequate remedy, would occur in the event that any Party does not perform its obligations under the provisions of this
Agreement in accordance with their specific terms or otherwise breaches such provisions. It is accordingly agreed that each Party shall
be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and
to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without proof
of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each Party agrees that it will
not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant to the terms
of this Agreement on the basis that the other Parties have an adequate remedy at law or an award of specific performance is not an appropriate
remedy for any reason at law or equity.

 

13.          No
Third Party Beneficiaries. This Agreement shall be for the sole benefit of the Parties and their respective successors and permitted
assigns and is not intended, nor shall be construed, to give any Person, other than the Parties and their respective successors and assigns,
any legal or equitable right, benefit or remedy of any nature whatsoever by reason of this Agreement. Nothing in this Agreement, expressed
or implied, is intended to or shall constitute the Parties as partners or participants in a joint venture.

 

14.          Miscellaneous.

 

(a)            Sections
9.4 (Governing Law), 9.6 (Construction; Interpretation), 9.9 (Severability), 9.10 (Counterparts; Electronic Signatures), 9.14 (Waiver
of Jury Trial) and 9.15 (Submission to Jurisdiction) of the Business Combination Agreement are incorporated herein by reference and shall
apply to this Agreement, mutatis mutandis.

 

(b)            All
representations, warranties, indemnities, covenants, agreements and obligations given or entered into by Stockholders, Chen, or Aisiku
in this Agreement are given or entered into on a several basis, such that each of Stockholders, Chen, or Aisiku (i) is responsible
for his or its own obligations separately from any other Party’s liability, and (ii) is only liable in respect of his or its
own acts and defaults and not those of any other Party.

 

[Signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	COMPANY:
	 	 
	 	DIGITAL HEALTH ACQUISITION CORP.,
 a Delaware corporation
	 	 
	 	By:	/s/ Scott Wolf
	 	Name:	Scott Wolf
	 	Title:	Chief Executive Officer

 

[Signature
Page to Amended and Restated Transaction Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have executed and delivered this Agreement as of the date first above written.

 

	 	STOCKHOLDERS:
	 	 
	 	IMOIGELE AISIKU
	 	 
	 	/s/ IMOIGELE AISIKU
	 	 
	 	ANTHONY BURNETT
	 	 
	 	/s/ ANTHONY BURNETT
	 	 
	 	MILTON CHEN
	 	 
	 	/s/ MILTON CHEN
	 	 
	 	SALESFORCE, INC.
	 	 
	 	By:	/s/ John Somorjai
	 	Name:	John Somorjai
	 	Title:	Executive Vice President, Corporate Development and Salesforce Ventures

 

[Signature
Page to Amended and Restated Transaction Support Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties have executed
and delivered this Agreement as of the date first above written.

 

	 	CHEN:
	 	 
	 	MILTON CHEN
	 	 
	 	/s/ MILTON CHEN
	 	 
	 	 
	 	AISIKU:
	 	 
	 	IMOIGELE AISIKU
	 	 
	 	/s/ IMOIGELE AISIKU

 

[Signature
Page to Amended and Restated Transaction Support Agreement]

 

     

     

    

 

SCHEDULE A

 

	Stockholder	 	Number of
 Shares of
 iDoc
 Common Stock	 	 	Number of
 Shares of
 VSee Common
 Stock	 	 	Number of
 Shares of
 VSee Series
 A-1 Preferred
 Stock	 
	Imoigele Aisiku 
c/o iDoc Virtual Telehealth Solutions, Inc.
 2311 West Main Street 
Houston, Texas 77098 
	 	 	3,557	 	 	 	0	 	 	 	0	 
	Anthony Burnett 
c/o iDoc Virtual Telehealth Solutions, Inc.
 2311 West Main Street 
Houston, Texas 77098 
	 	 	680	 	 	 	0	 	 	 	0	 
	Milton Chen 
c/o VSee Lab, Inc.
 3188 Kimlee Drive 
San Jose, CA 95132 
	 	 	0	 	 	 	7,186,237	 	 	 	0	 
	Salesforce, Inc.
 415 Mission St, 3rd Floor
 San Francisco, CA 94105
 Attention: Omar S. Alam, Vice President, M&A Legal and Associate General Counsel
 Email:
ventureslegal@salesforce.com
	 	 	0	 	 	 	0	 	 	 	1,195,019

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]